# Elevated serum soluble α3(IV)NC1 correlates with kidney injury and worse outcome in patients with anti-glomerular basement membrane disease

**Authors:** Huang Kuang, Hong-shan Wan, Zhao Cui, Ming-hui Zhao, Xiao-yu Jia

PMC · DOI: 10.3389/fimmu.2026.1728059 · Frontiers in Immunology · 2026-02-20

## TL;DR

High levels of a protein called soluble α3(IV)NC1 in the blood are linked to kidney damage and worse outcomes in patients with a severe autoimmune kidney disease.

## Contribution

This study is the first to show that elevated serum soluble α3(IV)NC1 correlates with disease severity and poor kidney outcomes in anti-GBM disease.

## Key findings

- Serum soluble α3(IV)NC1 levels were significantly higher in anti-GBM disease patients compared to healthy individuals.
- Elevated soluble α3(IV)NC1 was associated with worse kidney outcomes and correlated with markers of disease severity.
- Kaplan–Meier analysis showed patients with high soluble α3(IV)NC1 had a higher risk of poor kidney outcomes.

## Abstract

Anti-glomerular basement membrane (GBM) disease is the most severe form of autoimmune kidney diseases characterized by pathogenic autoantibodies against GBM component, α3(IV)NC1. However, the status of circulating soluble α3(IV)NC1 (also known as tumstatin) in patients with anti-GBM disease and its clinical relevance remain unclear. The aim of this study was to investigate the serum soluble α3(IV)NC1 level [ss-α3(IV)NC1] in patients with anti-GBM disease, and to analyze its association to clinical characteristics.

Seventy patients with anti-GBM disease and 30 healthy individuals were enrolled. Ss-α3(IV)NC1 was measured by enzyme-linked immunosorbent assay. The level was compared and analyzed with clinical-pathological features and kidney outcome, and the statistical significance was determined.

Ss-α3(IV)NC1 concentrations were elevated in 41 (58.6%) patients with anti-GBM disease and 0 (0.0%) healthy individuals. They were significantly higher in patients with anti-GBM disease (18.32 ± 9.56 ng/mL) than those in healthy individuals (5.84 ± 2.78 ng/mL) (P < 0.001). Ss-α3(IV)NC1 correlated with age (r = 0.385, P = 0.001), serum creatinine (r = 0.286, P = 0.016), eGFR (r = -0.304, P = 0.010), crescent percentage (r = 0.339, P = 0.030), and normal glomeruli percentage (r = -0.354, P = 0.023). Kaplan–Meier analysis revealed that patients with elevated ss-α3(IV)NC1 had a worse kidney outcome than those with normal level (P = 0.011).

The ss-α3(IV)NC1 was abnormally elevated in patients with anti-GBM disease. Elevated ss-α3(IV)NC1 was associated with the disease severity in anti-GBM disease. The role of these elevated levels warrants further investigation.

## Linked entities

- **Diseases:** anti-glomerular basement membrane disease (MONDO:0009303)

## Full-text entities

- **Genes:** MPO (myeloperoxidase) [NCBI Gene 4353], PRTN3 (proteinase 3) [NCBI Gene 5657] {aka ACPA, AGP7, C-ANCA, CANCA, MBN, MBT}, TCIRG1 (T cell immune regulator 1, ATPase H+ transporting V0 subunit a3) [NCBI Gene 10312] {aka ATP6N1C, ATP6V0A3, Atp6i, OC-116kDa, OC116, OPTB1}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, MMP12 (matrix metallopeptidase 12) [NCBI Gene 4321] {aka HME, ME, MME, MMP-12}, PXDN (peroxidasin) [NCBI Gene 7837] {aka ASGD7, COPOA, D2S448, D2S448E, MG50, PRG2}, COL4A3 (collagen type IV alpha 3 chain) [NCBI Gene 1285] {aka ATS2, ATS3, ATS3A, ATS3B, BFH2}
- **Diseases:** ESKD (MESH:D007676), glomerulonephritis (MESH:D005921), necrosis (MESH:D009336), autoimmune kidney diseases (MESH:D007674), lung cancer (MESH:D008175), diabetes (MESH:D003920), Lung hemorrhage (MESH:D008171), AAV (MESH:D056648), tumor (MESH:D009369), Anti-GBM disease (MESH:D019867), hematuria (MESH:D006417), autoimmune attack (MESH:D001327), bleeding (MESH:D006470), nephritis (MESH:D009393), kidney function injury (MESH:D058186), anti (MESH:D006679)
- **Chemicals:** creatinine (MESH:D003404)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963254/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963254/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963254/full.md

---
Source: https://tomesphere.com/paper/PMC12963254